Literature DB >> 2212364

Natural history of hypertrophic cardiomyopathy in the elderly.

W P Fay1, C P Taliercio, D M Ilstrup, A J Tajik, B J Gersh.   

Abstract

The prognosis of patients diagnosed as having hypertrophic cardiomyopathy at advanced age has not been well defined. This study details follow-up information obtained for 95 patients initially diagnosed as having hypertrophic cardiomyopathy at age greater than or equal to 65 years. Seventy-five percent of patients were symptomatic, as defined by the presence of chest pain, dyspnea or syncope, and the mean ventricular septal thickness was 20 mm. The median duration of follow-up study was 4.2 years. The survival rate at 1 and 5 years was 95% and 76%, respectively, which was not significantly different from that an age- and gender-matched control group. Of patients presenting with New York Heart Association functional class I or II dyspnea, only 18% progressed to class III or IV during the follow-up period. However, patients presenting with class III dyspnea had a 1 year mortality rate of 36%, significantly higher than that of control subjects (p less than 0.003). Of the echocardiographic variables, indexed left atrial size was most strongly associated with reduced survival (p less than 0.008). These results suggest that the prognosis of elderly patients with hypertrophic cardiomyopathy is generally favorable. Certain clinical and echocardiographic variables appear to be of use in identifying patients with a less favorable prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2212364     DOI: 10.1016/s0735-1097(10)80328-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Non-surgical ablation of the ventricular septum for the treatment of hypertrophic cardiomyopathy.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1995-11

2.  Natural history of hypertrophic cardiomyopathy.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

3.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

4.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

5.  Efficacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy.

Authors:  Laila Cheddadi; Olivier Lairez; Thibault Lhermusier; Francisco Campelo-Parada; Michel Galinier; Didier Carrié; Nicolas Boudou
Journal:  Clin Interv Aging       Date:  2017-03-03       Impact factor: 4.458

6.  Hypertrophic Cardiomyopathy in Elderly Individuals: Is It a Rose by Another Name?

Authors:  Deacon Z J Lee; Harry Rakowski
Journal:  J Am Heart Assoc       Date:  2021-01-28       Impact factor: 5.501

Review 7.  The Molecular Mechanisms of Mutations in Actin and Myosin that Cause Inherited Myopathy.

Authors:  Steven Marston
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.